Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

REN 001 - Reneo Pharmaceuticals

Drug Profile

REN 001 - Reneo Pharmaceuticals

Alternative Names: HPP-593; REN-001 - Reneo Pharmaceuticals

Latest Information Update: 29 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novo Nordisk
  • Developer High Point Pharmaceuticals; vTv Therapeutics LLC
  • Class Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor delta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Muscle fatigue
  • No development reported Diabetes mellitus; Dyslipidaemias

Most Recent Events

  • 06 Feb 2019 Reneo Pharmaceuticals plans a phase I trial for Fatty acid oxidation disorders in March 2019 (NCT03833128)
  • 21 Dec 2017 REN 001 licensed to Reneo Pharmaceuticals worldwide
  • 19 Jan 2016 No development reported - Phase-I for Diabetes mellitus in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top